Buscar ubicaciones
Para conocer los horarios, visitas sin turno y citas.No se pudo cargar la navegación global.
Synonyms
- Beta Apolipoprotein
Expected Turnaround Time
1 - 2 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
For more information, please view the literature below.
Spanning the Continuum of Cardiovascular Care
Apolipoprotein B (ApoB): Refining Cardiovascular Risk Management and LDL Treatment Decisions
Specimen Requirements
Specimen
Serum (preferred) or plasma
Volume
2 mL
Container
Red-top tube, gel-barrier tube, green-top (heparin) tube, or lavender-top (EDTA) tube
Collection
Separate serum or plasma from cells. Transfer specimen to a plastic transport tube.
Storage Instructions
Maintain specimen at room temperature.
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Patient Preparation
Patient must be fasting 12 to 14 hours.
Causes for Rejection
Specimen from nonfasting patient
Test Details
Use
LDL and its major protein, apolipoprotein B, play an essential role in lipid transport and metabolism. Apo B may regulate cholesterol synthesis through its interaction with specific cell membrane receptors and by inhibition of HMG Co A reductase. This enzyme has been identified as the rate controlling enzyme in cholesterol biosynthesis. Apo B may be important in the genesis of atherosclerosis and its quantitation useful in the evaluation of patients at risk for or having coronary atherosclerosis (CAD). High levels indicate increased risk for CAD.
Methodology
Immunologic
Reference Interval
Apolipoprotein B (mg/dL) | |||
|---|---|---|---|
Desirable | Borderline High | High | Very High |
<90 | 90 – 99 | 100 – 130 | >130 |
ASCVD Risk Category | Therapeutic Target APO B (mg/dL) |
|---|---|
Very High Risk | <80 (if extreme risk <70) |
High Risk | <90 |
Moderate Risk | <90 |
References
Colantonio DA, Kyriakopoulou L, Chan MK, et al. Closing the gaps in pediatric laboratory reference intervals: A CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clin Chem. 2012 May; 58(5):854-868.22371482
Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009 Mar;55(3):407-419.19168552
Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015 Mar-Apr;9(2):129-169.25911072
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 167015 | Apolipoprotein B | 1884-6 | 167015 | Apolipoprotein B | mg/dL | 1884-6 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf